MedTrace Logo

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

NCT00404092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2013-07-31

Study results available
· View outcomes & findings →

Summary

This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.

Conditions

  • Invasive Aspergillosis

Interventions

DRUG

caspofungin

i.v.

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Oliver A. Cornely, MD · Klinikum der Universität zu Köln

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Belgium
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00404092 on ClinicalTrials.gov